This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world's top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy.
pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the launch of ClinFAST, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.
Eddie Lai Eddie Lai (SPH’19), who studied healthcare management and pharmaceutical development, delivery, and access while a student at SPH, recommends the podcast Freakonomics M.D. Freakonomics M.D. with Bapu Jena, a health economist, practicing internal medicine physician, and professor of health care policy.
President Trump's tariffs in China are in place and hitting all products imported from the country including a number of pharmaceutical drugs that Americans rely upon. pharmaceutical companies turned to other manufacturing pursuits. Chinese imports account for a significant proportion of U.S. prescriptions and over the counter drugs.
the pharmaceutical industry). 30 Unfortunately, one of the most common grifts in this industry is to hype up the danger of a new disease, then have a new biotech company present a "cure" (or vaccine) for the disease and offer a large number of shares that investors eagerly buy up (spiking the price). one large study found 37.8%
Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that he had tapped vaccine skeptic Robert F. The SPDR S&P Biotech ETF, which tracks the biotech sector, has dropped 3.7 Shares in major pharmaceutical companies are down as well: Pfizer has fallen 4.6
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content